LSNE completes expansion to meet validated storage and cold chain options

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ 10174593_258)
(Image: Getty/ 10174593_258)

Related tags: Cold chain, Quality control, cGMP, Gmp, Manufacturing, analytical

Growing need for validated storage capacity sees Lyophilization Services of New England complete an expansion its cGMP storage capabilities at its New Hampshire site.

Lyophilization Services of New England (LSNE), a contract development and manufacturing organization (CDMO), continues its ongoing expansion at its Bedford, New Hampshire site, adding increased short- and long-term current good manufacturing practice (cGMP) storage capabilities. The expanded facility meets the requirements of controlled room temperature, refrigerated, and frozen temperature-sensitive products.

Additionally, the growth project has added ICH stability chambers for standard storage conditions including -20°C, 2-8°C, 25°C/60%RH, 30°C/65%RH, 40°C/75%RH.

Jeff Clement, VP of business development at LSNE, told Outsourcing-Pharma, “More and more of our clients told us that they sometimes struggle finding long term validated storage options. Our capacity was limited, so this increase in validated storage space it already working out very well for our existing clients.”

The Bedford site also houses LSNE’s quality control laboratory for analytical and microbiology testing services. With the addition of the cGMP storage capabilities at the site, LSNE said it will be able to provide a solution to address its clients’ cold chain storage requirements.

Shawn Cain, COO at LSNE, said, “Having 80,000 cubic feet of additional on-site cGMP temperature-controlled storage will ensure products reaching patients around the world are stored properly. We understand dependable storage is critical to our clients' products.”

Aside from its four New Hampshire facilities, LSNE has sites in Wisconsin and Spain.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars